Literature DB >> 33098452

Effects of anesthetic agents on contractions of the pregnant rat myometrium in vivo and in vitro.

Motonobu Kimizuka1, Yasuyuki Tokinaga2, Ryu Azumaguchi2, Kosuke Hamada2, Satoshi Kazuma2, Michiaki Yamakage2.   

Abstract

BACKGROUND: Several anesthetic agents are used in cesarean sections for both regional and general anesthesia purposes. However, there are no data comparing the in vivo effects of propofol, sevoflurane, and dexmedetomidine on the contraction of the myometrium in pregnant rats. The aim of this study was to investigate the effect of these anesthetic agents on myometrial contraction and elucidate the underlying mechanisms.
METHODS: Contraction force and frequency changes in response to propofol, dexmedetomidine, or sevoflurane were evaluated in vivo and in vitro. To test the effect of arachidonic acid on myometrial contraction enhanced by dexmedetomidine, changes in myometrial contraction with dexmedetomidine after administration of indomethacin were evaluated. The amount of phosphorylated myosin phosphatase target subunit 1 (MYPT1) in the membrane fraction was expressed as a percentage of the total fraction by Western blot analysis.
RESULTS: This study demonstrated that dexmedetomidine enhances oxytocin-induced contraction in the myometrium of pregnant rats, whereas propofol and sevoflurane attenuate these contractions. The dexmedetomidine-induced enhancement of myometrial contraction force was abolished by the administration of indomethacin. Propofol did not affect oxytocin-induced MYPT1 phosphorylation, whereas sevoflurane attenuated oxytocin-induced MYPT1 phosphorylation.
CONCLUSIONS: Inhibition of myofilament calcium sensitivity may underlie the inhibition of myometrial contraction induced by sevoflurane. Arachidonic acid may play an important role in the enhancement of myometrial contraction induced by dexmedetomidine by increasing myofilament calcium sensitivity. Dexmedetomidine may be used as a sedative agent to promote uterine muscle contraction and suppress bleeding after fetal delivery.

Entities:  

Keywords:  Dexmedetomidine; Myometrial contraction; Pregnant rat

Year:  2020        PMID: 33098452      PMCID: PMC7840642          DOI: 10.1007/s00540-020-02866-9

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  4 in total

1.  Rates of awakening from anesthesia with I-653, halothane, isoflurane, and sevoflurane: a test of the effect of anesthetic concentration and duration in rats.

Authors:  E I Eger; B H Johnson
Journal:  Anesth Analg       Date:  1987-10       Impact factor: 5.108

2.  Mechanism of the ropivacaine-induced increase in intracellular Ca2+ concentration in rat aortic smooth muscle.

Authors:  Y Tokinaga; K Ogawa; J Yu; T Kuriyama; T Minonishi; Y Hatano
Journal:  Acta Anaesthesiol Scand       Date:  2007-08-20       Impact factor: 2.105

3.  Alpha adrenergic receptor subtypes involved in prostaglandin synthesis are coupled to Ca++ channels through a pertussis toxin-sensitive guanine nucleotide-binding protein.

Authors:  C Nebigil; K U Malik
Journal:  J Pharmacol Exp Ther       Date:  1993-08       Impact factor: 4.030

Review 4.  Pathology of asthma.

Authors:  Makoto Kudo; Yoshiaki Ishigatsubo; Ichiro Aoki
Journal:  Front Microbiol       Date:  2013-09-10       Impact factor: 5.640

  4 in total
  3 in total

1.  Impact of anesthetic agents on the amount of bleeding during dilatation and evacuation: A systematic review and meta-analysis.

Authors:  Hyun Ah Lee; Hiromasa Kawakami; Takahiro Mihara; Hitoshi Sato; Takahisa Goto
Journal:  PLoS One       Date:  2021-12-22       Impact factor: 3.240

Review 2.  General anesthesia for cesarean section: are we doing it well?

Authors:  Sung Uk Choi
Journal:  Anesth Pain Med (Seoul)       Date:  2022-07-26

3.  Effects of Solvents, Emulsions, Cosolvents, and Complexions on Ex Vivo Mouse Myometrial Contractility.

Authors:  Christopher J Hansen; Shajila Siricilla; Naoko Boatwright; Jackson H Rogers; Melissa E Kumi; Jennifer Herington
Journal:  Reprod Sci       Date:  2021-04-14       Impact factor: 3.060

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.